AKT1 and lip and oral cavity carcinoma: In addition, they found significantly reduced p-AKT levels and increased PTEN levels in antagomiR-31-5p treated xenografts, indicating that miR-31-5p could be a therapeutic target in oral cancer via the PTEN/AKT pathway [61].